This is a Phase I, open-label, single-site trial to evaluate the drug release, using
Scintigraphic images and mesalazine plasma levels (PK) in healthy subjects. Overall, nine [9]
subjects per prototype coating (a total of 18) will be evaluated. Eligible subjects will be
assigned in a 1:1 ratio to receive radio-labelled TP05; the first 9 subjects will receive
formulation B and the second 9 subjects will receive formulation A. The subjects will be
treated once with the radio-labelled study medication.